NCT05061277View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Recifercept in Healthy Chinese Participants

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 25, 2023

Primary Completion Date

December 12, 2023

Study Completion Date

June 16, 2024

Conditions
Healthy
Interventions
DRUG

Recifercept

A lyophilized powder for solution for injection

Trial Locations (2)

200040

Huashan Hospital Fudan University, Shanghai

201107

Huashan Hospital Fudan University, Shanghai

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05061277 - Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Recifercept in Healthy Chinese Participants | Biotech Hunter | Biotech Hunter